Maintenance Therapy for Acute Myelogenous Leukaemia

Authors

  • Md Abdul Aziz Associate Professor, Department of Haematology, BSMMU, Dhaka
  • Naseeb M Irshadullah Resident, Phase-B (Haematology), Department of Haematology, BSMMU, Dhaka
  • Mohammad Ali Resident Physician, Department of Haematology, DMCH, Dhaka
  • Shafiqul Islam Medical Officer, Department of Haematology, BSMMU, Dhaka
  • Sirajul Islam Associate Professor, Department of Haematology, Mymensingh Medical College, Mymensingh
  • Masuda Begum Chairman, Department of Haematology, BSMMU, Dhaka
  • Rafia Afrose Medical Officer, Department of Haematology, Dhaka Medical College Hospital, Dhaka
  • Abul Fazal Mohammad Helal Assistant Professor, Department of Medicine, Sir Salimullah Medical College, Mitford, Dhaka

DOI:

https://doi.org/10.3329/jdmc.v24i1.29567

Keywords:

Acute myelogenous leukaemia (AML), maintenance therapy

Abstract

Acute myelogenous leukaemia (AML) is one of the deadliest malignancies of mankind. With optimum treatment long term survival is still less than half the patients treated. Except acute promyelocytic leukaemia (AML M3), maintenance therapy in recent protocols are not recommended. This article discusses potential benefit of maintenance therapy for all AML patients, especially in facilities available in developing countries like Bangladesh.

J Dhaka Medical College, Vol. 24, No.1, April, 2015, Page 67-72

Downloads

Download data is not yet available.
Abstract
54
PDF
41

Author Biography

Md Abdul Aziz, Associate Professor, Department of Haematology, BSMMU, Dhaka



Downloads

Published

2016-09-07

How to Cite

Aziz, M. A., Irshadullah, N. M., Ali, M., Islam, S., Islam, S., Begum, M., Afrose, R., & Helal, A. F. M. (2016). Maintenance Therapy for Acute Myelogenous Leukaemia. Journal of Dhaka Medical College, 24(1), 67–72. https://doi.org/10.3329/jdmc.v24i1.29567

Issue

Vol. 24 No. 1 (2015)

Section

Review Articles